iSpecimen Seeks Reverse Split, Massive Share Increase to Bolster Finances

TL;DR

**ISPC is desperate for cash and Nasdaq compliance, so they're proposing a massive reverse split and dilutive financing that will crush existing shareholders.**

AI Summary

iSpecimen Inc. (ISPC) is convening a Special Meeting on October 30, 2025, to address critical financial and corporate governance issues. The company seeks stockholder approval for a reverse stock split at a ratio between 1:10 and 1:100, aimed at increasing its per-share price to meet Nasdaq listing requirements. Concurrently, ISPC proposes to increase its authorized capital stock from 250,000,000 to 1,000,000,000 shares, providing flexibility for future capital raises. The filing also details proposals to approve potential issuances of common stock exceeding 19.99% of outstanding shares in non-public financings and through an equity line of credit, both potentially below Nasdaq's Minimum Price, to secure necessary funding. Additionally, ISPC plans to amend outstanding convertible securities to raise the conversion price floor from 50% to 80% of the lowest VWAP, which could reduce dilution from conversions. These measures collectively aim to bolster the company's financial stability and maintain its public listing.

Why It Matters

This DEF 14A filing is crucial for iSpecimen Inc. investors as it outlines a series of proposals designed to address potential delisting risks and secure future funding. The proposed reverse stock split, ranging from 1:10 to 1:100, directly impacts share price and liquidity, potentially making the stock more attractive to institutional investors but also signaling underlying financial distress. The substantial increase in authorized shares and approval for significant dilutive financing (exceeding 19.99% below Nasdaq's Minimum Price) could severely dilute existing shareholders, impacting their ownership percentage and the value of their holdings. Competitors in the biospecimen procurement market, such as Bio-Techne or Discovery Life Sciences, will be watching to see if ISPC can stabilize its financial position and continue to compete effectively.

Risk Assessment

Risk Level: high — The filing indicates high risk due to multiple proposals that could lead to significant shareholder dilution and reflect underlying financial instability. The proposed reverse stock split (1:10 to 1:100) is often a last resort to meet Nasdaq's minimum bid price requirement, suggesting the stock is trading at a very low price. Furthermore, seeking approval to issue shares exceeding 19.99% of outstanding common stock in non-public financings and via an equity line of credit, potentially below the Nasdaq Minimum Price, signals a strong need for capital that could substantially dilute current shareholders.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed share increase and financing arrangements. Consider selling positions if you are risk-averse, as these actions often precede further stock price declines. Monitor the outcome of the Special Meeting and any subsequent financing announcements closely.

Key Numbers

• 1:10 to 1:100 — Reverse Stock Split Ratio (Range for proposed reverse stock split to increase per-share price.)
• 250,000,000 — Current Authorized Shares (Number of shares currently authorized for issuance.)
• 1,000,000,000 — Proposed Authorized Shares (New number of shares proposed to be authorized, a 300% increase.)
• 19.99% — Nasdaq Listing Rule Threshold (Percentage of outstanding common stock that can be issued without further shareholder approval under Nasdaq rules, which ISPC seeks to exceed.)
• 50% — Current Conversion Price Floor (Current floor for conversion price of outstanding convertible securities relative to VWAP.)
• 80% — Proposed Conversion Price Floor (New proposed floor for conversion price of outstanding convertible securities relative to VWAP, reducing potential dilution.)
• 3,979,517 — Shares Outstanding (Number of common shares outstanding and entitled to vote as of July 25, 2025.)
• 34% — Quorum Requirement (Percentage of voting power required for a quorum at the Special Meeting.)
• October 30, 2025 — Special Meeting Date (Date when stockholders will vote on these critical proposals.)
• $0.0001 — Par Value per Share (Par value of iSpecimen Inc. common stock.)

Key Players & Entities

• iSpecimen Inc. (company) — Registrant seeking stockholder approval
• Robert Bradley Lim (person) — Chief Executive Officer of iSpecimen Inc.
• Nasdaq (regulator) — Exchange with listing rules (Rule 5635(d))
• SEC (regulator) — Securities and Exchange Commission
• Woburn, MA (location) — Headquarters of iSpecimen Inc.
• October 30, 2025 (date) — Date of the Special Meeting of Stockholders
• July 25, 2025 (date) — Record Date for voting eligibility
• 250,000,000 (dollar_amount) — Current authorized shares of capital stock
• 1,000,000,000 (dollar_amount) — Proposed authorized shares of capital stock
• 3,979,517 (dollar_amount) — Shares of common stock outstanding on Record Date

FAQ

Risk Factors

• Failure to Meet Nasdaq Listing Requirements [high — financial]: The company is seeking approval for a reverse stock split to increase its per-share price to meet Nasdaq listing requirements. Failure to achieve this could result in delisting, significantly impacting liquidity and investor confidence.
• Need for Capital and Dilution Concerns [high — financial]: ISPC proposes to increase authorized shares and potentially issue over 19.99% of outstanding shares in non-public financings or via an equity line of credit, possibly below Nasdaq's Minimum Price. This indicates a pressing need for capital, which could lead to significant dilution for existing shareholders.
• Amendments to Convertible Securities [medium — financial]: The company plans to amend outstanding convertible securities to raise the conversion price floor from 50% to 80% of the lowest VWAP. While intended to reduce dilution, this change could still result in substantial dilution if conversion occurs at prices significantly above the new floor.
• Compliance with Nasdaq Listing Rules [high — regulatory]: The proposed reverse stock split and potential share issuances are directly tied to maintaining compliance with Nasdaq's listing rules. Any misstep or failure to gain shareholder approval for these measures could lead to delisting.

Industry Context

The biotechnology and life sciences research support industry, where iSpecimen operates, is characterized by a need for efficient access to biological samples for research and development. Companies in this space often face challenges related to sample sourcing, quality control, and regulatory compliance. The market is competitive, with players ranging from large distributors to specialized niche providers.

Regulatory Implications

iSpecimen's proposals are heavily influenced by Nasdaq's listing requirements, particularly concerning minimum share price and shareholder approval thresholds for significant stock issuances. Failure to comply could lead to delisting, while the proposed share increases and equity financings must navigate securities regulations.

What Investors Should Do

1. Review the proposed reverse stock split ratio and its potential impact on share price and liquidity.
2. Evaluate the necessity and potential dilution from the proposed increase in authorized shares and equity issuances.
3. Understand the implications of amending convertible securities' conversion price floor.
4. Vote on the proposals at the Special Meeting on October 30, 2025.

Key Dates

• 2025-10-30: Special Meeting of Stockholders — Stockholders will vote on critical proposals including a reverse stock split, increase in authorized shares, and potential equity issuances, which are vital for the company's continued listing on Nasdaq and future financing flexibility.
• 2025-07-25: Record Date for Special Meeting — Establishes the list of stockholders entitled to vote at the Special Meeting.
• 2025-10-15: First Distribution of Proxy Materials — Informs stockholders about the upcoming meeting and the proposals to be voted upon, providing them with access to proxy materials.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. This is often done to increase the stock price. (iSpecimen is proposing a reverse stock split (ratio between 1:10 and 1:100) to meet Nasdaq's minimum per-share price requirement.)

Authorized Capital Stock

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter documents. (iSpecimen seeks to increase its authorized shares from 250,000,000 to 1,000,000,000 to provide flexibility for future capital raises.)

VWAP

Volume Weighted Average Price. It is the average price a stock has traded at throughout the day, based on both volume and price. It's often used as a benchmark. (The company proposes to adjust the conversion price floor of convertible securities to 80% of the lowest VWAP, impacting potential dilution.)

Equity Line of Credit

A financing arrangement where a company can draw down funds by issuing shares to an investor at pre-determined prices over a specified period, subject to certain conditions. (iSpecimen is seeking approval for potential issuances through an equity line of credit to secure necessary funding.)

Convertible Securities

Financial instruments, such as bonds or preferred stock, that can be converted into a predetermined amount of the issuer's common stock or cash. (iSpecimen plans to amend the conversion price floor of its outstanding convertible securities to potentially reduce future dilution.)

Par Value

A nominal value assigned to a share of stock by the company's charter. It has little relation to the market value of the stock. (The par value of iSpecimen's common stock is $0.0001 per share.)

Year-Over-Year Comparison

This filing (DEF 14A) focuses on critical proposals for an upcoming Special Meeting, indicating a proactive, albeit potentially concerning, financial situation. Unlike a typical annual report, it highlights urgent needs such as meeting Nasdaq listing requirements via a reverse stock split and securing future capital through increased authorized shares and potential dilutive issuances. The previous filing likely detailed historical financial performance, whereas this document outlines strategic maneuvers to address immediate financial stability and listing compliance challenges.

Key Financial Figures

• $0.0001 — nding shares of common stock, par value $0.0001 per share, at a ratio, ranging from one

Filing Documents

• ea0256032-03.htm (DEF 14A) — 483KB
• tispecimen.jpg (GRAPHIC) — 65KB
• tproxy_001.jpg (GRAPHIC) — 1225KB
• tproxy_002.jpg (GRAPHIC) — 835KB
• 0001213900-25-098780.txt ( ) — 3411KB

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   22 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE   23 Policies and Procedures for Related Party Transactions   23 Employee, Officer and Director Hedging   23 Anti-Takeover Effects of Certain Provisions of Our Certificate of Incorporation and Bylaws   23 Choice of Forum   24 Indemnification of Directors and Officers   24 Transfer Agent   25 HOUSEHOLDING   26 Annex A — Amendment to the Fourth Amended and Restated Certificate of Incorporation   A-1 Annex B — Proxy Card   B-1 i Table of Contents iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 08101 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 30, 2025 This proxy statement (the “Proxy Statement” or the “proxy materials”) are being furnished by and on behalf of the board of directors (the “Board” or the “Board of Directors”) of iSpecimen Inc. (the “Company,” “Corporation,” “iSpecimen,” “we,” “us,” or “our”), in connection with our 2025 special meeting of stockholders (the “Special Meeting”). This Notice of Special Meeting and Proxy Statement are first being distributed or made available, as the case may be, on or about October 15, 2025. NOTICE OF ELECTRONIC AVAILABILITY OF PROXY MATERIALS On or about October 15, 2025, we will mail to our stockholders of record at the close of business on July 25, 2025 (the “Record Date”) a Notice of Internet Availability of Proxy Materials (“Notice”) containing instructions on how to access proxy materials via the Internet and how to vote online. The

View Full Filing

View this DEF 14A filing on SEC EDGAR